Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

263 results about "Hypoglycemia" patented technology

A condition resulting when the blood glucose levels drop below the specified limits (4 mmol/L or 72mg/dL).

Personalized medical health service recommendation system based on big data analysis

The invention discloses a personalized medical health service recommendation system based on big data analysis, and belongs to the technical field of medical health services. The synchronization module is used for generating a standardized data stream according to dynamic blood glucose monitoring data and an original heart rate variability signal; the analysis module is used for generating a diet time sequence data stream according to the intake event timestamp; the blood glucose feature extraction module is used for extracting data from the standardized data stream; the insulin sensitivity analysis module is used for generating an insulin sensitivity factor matrix; the nutrition analysis module is used for generating a carbohydrate equivalent time distribution vector and a dietary fiber intake intensity value; the feature fusion module is used for generating a fusion feature vector according to the blood glucose drift trend coefficient, the insulin sensitive factor matrix and the carbohydrate equivalent time distribution vector; the risk assessment module is used for generating a hypoglycemia risk probability value according to the fusion feature vector; and the recommendation generation module is used for generating a personalized service recommendation set according to the hypoglycemia risk probability value.
Owner:CHINESE PEOPLES LIBERATION ARMY GENERAL HOSPITAL HAINAN HOSPITAL

Preparation method and application of glucose sensor based on acupuncture needle

The invention discloses a preparation method and application of a glucose sensor based on an acupuncture needle, the sensor is prepared based on a specific structural design and a molecular recognition mechanism by taking the acupuncture needle as a substrate, and high-specificity and high-sensitivity detection of glucose concentration is realized through drain current change. According to the present invention, the biosensor has the ultra-wide dynamic detection range (0-40 mmol.L <-1 >), covers the clinical range from hypoglycemia to severe hyperglycemia, has the low detection limit of 54 mol.L <-1 >, has excellent grid regulation and control ability, shows the significant on-off ratio and the rapid response characteristic during the detection process, and meets the requirements of the biosensor on sensitivity and real-time performance; and the device has quick response capability to grid voltage change, so that the device has good stability and repeatability under repeated operation, and a direction and a basis can be provided for the development of a blood glucose monitoring technology with continuous, real-time and accurate characteristics.
Owner:INNER MONGOLIA UNIV FOR THE NATITIES

Self-crosslinking hydrogel with tertiary amine group as well as preparation and application of self-crosslinking hydrogel

The invention discloses a self-crosslinking hydrogel with a tertiary amine group and preparation and application thereof, and belongs to the field of biomedical polymer materials, the self-crosslinking hydrogel comprises aminophenylboronic acid modified oxidized glucan, tertiary amine compound modified oxidized glucan and a solvent medium; the preparation method comprises the following steps: dissolving amino phenylboronic acid modified oxidized dextran and tertiary amine compound modified oxidized dextran in a solvent medium, mixing, standing for a certain time, and carrying out self-crosslinking to obtain the self-crosslinking hydrogel with tertiary amine groups. A cross-linking point (phenylboronic acid) of the gel network is a response unit of glucose. In addition, the hydrogel can effectively avoid uncontrollable drug release caused by non-responsive factors, and the response release efficiency of the drug is improved; by loading the hypoglycemic drug insulin to be applied to the treatment research process of diabetes, the occurrence of hypoglycemia can be avoided, and meanwhile, the possibility is provided for realizing intelligent controlled release of insulin through blood glucose response.
Owner:HANGZHOU NORMAL UNIVERSITY

Activity mode for artificial pancreas system

A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and / or a detected location of the user.
Owner:INSULET CORP

Systems and methods for delayed meal boluses in automated insulin delivery

ActiveUS12567493B2Drug and medicationsNutrition controlDiabetes TherapyHypoglycemia
Disclosed herein are apparatuses and methods that can provide a delayed bolus calculator for use in closed loop diabetes therapy that can account for additional factors not taken into account in regular meal bolus calculations when a user wants to deliver a meal bolus a period of time after a meal was consumed. A delayed bolus calculator can enable the user to enter a period of time since the meal was consumed in addition to the number of carbohydrates consumed in a meal. This enables the system to account for the amount of increased insulin from the closed loop algorithm in response to the meal and / or the time since the meal to ensure that the risk of hypoglycemia is mitigated while still reducing hyperglycemia.
Owner:TANDEM DIABETES CARE INC

Blood glucose real-time monitoring and hypoglycemia early warning system in hemodialysis

The invention relates to the technical field of blood glucose monitoring, and discloses a blood glucose real-time monitoring and hypoglycemia early warning system in hemodialysis, which comprises dialysis blood real-time data: acquiring the change of blood glucose of a dialysis patient in real time through a blood glucose monitoring device of a blood glucose monitor connected with a hemodialysis machine; patient body data: acquiring basic data of a patient body, and acquiring data of weight, age, height and related blood glucose; acquiring and recording medicine data and disease history of the patient, and acquiring and recording past medicine and disease history of the patient; the patient data transceiving device is used for compressing and transmitting the acquired data through a data receiving device outside the hemodialysis machine; and dialysis data is stored, processed and uploaded information is stored, attention fatigue caused by real-time monitoring of blood glucose of a patient by medical staff is reduced, and dialysis blood glucose prediction accuracy is improved.
Owner:ZHANGJIAGANG AOYANG HOSPITAL CO LTD

Intelligent insulin closed-loop infusion system for type 1 diabetes

The invention provides an intelligent insulin closed-loop infusion system for type 1 diabetes mellitus, and relates to the technical field of diabetes mellitus treatment equipment. The system comprises a blood glucose monitoring module, a control module, an insulin infusion module, a user interaction module, a wireless communication module and a power module, and closed-loop precise infusion of insulin is achieved through cooperation of the multiple modules. Wherein a closed-loop algorithm based on a dynamic basic rate formula is arranged in the control module, and the insulin infusion amount can be dynamically adjusted in combination with an LSTM blood glucose prediction model and a metabolic parameter least square method updating unit; the insulin infusion module adopts a micro peristaltic pump controlled by PWM (Pulse Width Modulation) and a current monitoring type blockage detection unit, so that the infusion precision and safety are guaranteed. According to the system, the blood glucose standard reaching time proportion can be increased to 78%, the hypoglycemia occurrence frequency is reduced to 0.8 times per week, the system is remarkably superior to a traditional insulin pump and a simple closed-loop system, meanwhile, the system has the advantages of being long in sensor service life and low in power consumption, and the treatment convenience and safety of type 1 diabetes patients are improved.
Owner:AFFILIATED HOSPITAL OF JIANGSU UNIV

System and method for automated insulin delivery using artificial neural network

An automated insulin delivery system provides an insulin injection that is computed by adding (i) the recommendation of an artificial neural network trained to mimic a constrained model predictive controller dosing rule from a neural network implementing an artificial pancreas (ii) a hypoglycemia mitigation system includeds a correction (one dose computed as the correction down to 110mg / dl based on prevailing continuous glucose monitoring and once an hour at most, unless there is a triggering BPS and G>180 mg / dl), and (iii) the current basal rate (output of the Performance Assessment System, (PAS)); that amount is then saturated by the Safety Supervision System, SSM. Finally, a priming bolus from the Bolus Priming System, BPS, is added to the total if the conditions for large glycemic excursions are detected, also saturated by SSM.
Owner:UNIV OF VIRGINIA PATENT FOUND +8

Glucose-responsive molecular connector, and preparation method therefor and use thereof

Provided in the present invention is a glucose-responsive molecular connector, and a preparation method therefor and the use thereof. A brand-new glucose-responsive molecular connector is formed by the esterification of a phenylboronic acid analogue and a 1,3-diol structure. The compound can be directly biolinked to insulin by amidation and has a very good glucose-responsive function, wherein glucose at a high concentration competes with the 1,3-diol structure for binding to phenylboronic acid, so that the solubility of insulin is increased and the release of insulin is promoted, and when the glucose is at a low concentration, only a small amount of insulin is in a free state, thereby reducing the occurrence of hypoglycemia. The compound achieves the glucose response of insulin by means of a brand-new mechanism, causing the glucose response effect more sensitive. Moreover, the compound has the advantages of simple structure, being easy to prepare and low cost, and has great clinical application value.
Owner:ZHEJIANG UNIV

Test paper for rapidly detecting blood glucose and preparation method of test paper

The invention belongs to the technical field of blood glucose test paper, and particularly relates to rapid blood glucose detection test paper and a preparation method thereof. The blood glucose test paper is composed of a blood glucose test paper impregnation liquid and a test paper base material, wherein the test paper base material is composed of 10-20% of graphite powder, 10-15% of polyurethane resin, 5-10% of polybutylene terephthalate, 5-10% of polytrimethylene terephthalate, 5-10% of polyethylene, 5-10% of hydroxyethyl cellulose and 45-60% of ethylene glycol monobutyl ether; the blood glucose test strip impregnation liquid consists of 40-45% of phosphate buffer, 2-3% of glucose dehydrogenase, 40-45% of normal saline, 0.5-1% of ferric oxide, 0.5-1% of cobalt oxide, 2-3% of ascorbic acid and 1-3% of m-xylylenediamine; the prepared blood glucose test paper can still provide a more reliable result under the condition that blood glucose fluctuates greatly, has good stability, is slightly influenced by environmental factors, can give a result within four to five seconds, is reliable in measurement result, facilitates a user to know the blood glucose level in time, and is convenient for the user to use. And a patient can be helped to take measures quickly when the symptom of hypoglycemia or hyperglycemia occurs, so that crisis is avoided.
Owner:GUANGDONG TRANSTEK MEDICAL ELECTRONICS CO LTD

Foot temperature and humidity change-based diabetes blood glucose fluctuation trend prediction method

The invention relates to the technical field of non-invasive monitoring, in particular to a diabetes blood glucose fluctuation trend prediction method based on foot temperature and humidity change, which comprises the following steps: continuously collecting temperature, humidity and motion data of multiple areas of a foot through a foot wearable device, extracting a feature set related to blood glucose fluctuation from the preprocessed data, and calculating the blood glucose fluctuation trend according to the feature set; and fusing the feature set and context event information, inputting the fused feature set and context event information into a multi-task deep learning prediction model, visually displaying a prediction result in the forms of a trend arrow, a probability interval and a risk level, and triggering early warning in advance when a hyperglycemia or hypoglycemia event is predicted to be about to occur. The method is completely noninvasive and high in compliance, prospective trend prediction can be carried out based on existing diabetic foot monitoring wearable equipment, individual physiological characteristics of a user can be continuously learned through a built-in personalized self-adaptive mechanism, dynamic calibration is carried out on the model through incremental learning, and the prediction accuracy is improved. And the prediction precision is continuously improved along with the use time.
Owner:HANGZHOU BEIYI MEDICAL EQUIPMENT CO LTD

Hemodialysis fluid balance control method, device, electronic device and medium

The present invention discloses a hemodialysis fluid balance control method, device, electronic device, and medium, relating to the technical field of intelligent regulation. The hemodialysis fluid balance control method includes: in response to a patient experiencing a hypotensive event, determining whether the hypotensive event is caused by a hypoglycemic event; if the hypotensive event is caused by a hypoglycemic event, switching the patient's dialysate from a sugar-free dialysate to a sugar-containing dialysate; monitoring the patient's real-time blood glucose concentration; and controlling the dialysate flow rate during the patient's dialysis based on the real-time blood glucose concentration. The embodiments of the present application achieve the goal of reducing interference with hemodialysis while ensuring compensation for hypoglycemia.
Owner:南京汉科明德医疗科技有限公司

Rapid detection of hypoglycemia incidence using continuous glucose monitoring

Certain aspects of the present disclosure provide systems and techniques for rapid detection of repetitive metabolic events in a host based on measured analyte data provided by an analyte monitor worn by the host. An example system is configured to obtain measured glucose data of the host. A subset of the measured glucose data is determined, based on performing a filtering operation on the measured glucose data. A respective range of a likelihood of an occurrence of a metabolic is determined for each value within the subset of the measured glucose data. For at least one value within the subset of the measured glucose data, a state of the metabolic event is determined based in part on at least one of an upper bound or a lower bound of the respective range corresponding to the at least one value within the subset of the measured glucose data.
Owner:DEXCOM INC

Type 1 diabetes noninvasive hypoglycemia identification method based on intelligent wearable device

The invention belongs to the technical field of blood glucose recognition, and discloses a type 1 diabetes noninvasive hypoglycemia recognition method based on intelligent wearable equipment, which comprises the following steps: collecting multi-source physiological indexes and blood glucose data of a type 1 diabetes patient, and carrying out feature extraction and classification marking; constructing an objective function, and searching an optimal solution of the objective function in combination with leaf node splitting and information gain to obtain a scoring function and a feature division criterion; a dynamic hypoglycemia probability map is drawn according to the hypoglycemia occurrence probability, the overall situation and change of hypoglycemia events of the patient are visualized, and individualized hypoglycemia recognition and early warning are guided; a correction module is introduced, and individualized optimization is continuously carried out on the algorithm according to the fed-back fingertip blood glucose level. By the adoption of the type 1 diabetes noninvasive hypoglycemia recognition method based on the intelligent wearable device, the problems that an existing continuous glucose monitoring device is invasive, cannot be reused and is high in price in the blood glucose monitoring process are solved, and accurate recognition of hypoglycemia is achieved.
Owner:PEOPLES HOSPITAL PEKING UNIV +1

Timing and dosing improvements for diabetes management

In an embodiment, a system for of preventively treating hypoglycemia includes a continuous glucose monitoring (CGM) sensor system configured to generate measurements associated with a current glucose level of a patient. The system further includes one or more memories comprising executable instructions and one or more processors in data communication with the one or more memories. The one or more processors are configured to execute the executable instructions to receive, from the CGM sensor system, one or more measurements associated with the current glucose level of the patient and compute a sequence of preventive hypoglycemia treatments over a future time period based on the one or more measurements and a prediction of glucose control to be produced by the sequence. The one or more processors are further configured to prompt the patient with a first preventive hypoglycemia treatment in the sequence of preventive hypoglycemia treatments.
Owner:DEXCOM INC

Self-management method for pregnant women with gestational diabetes mellitus and related device

The invention discloses a self-management method for pregnant women with gestational diabetes mellitus and a related device. The method comprises the following steps: collecting comprehensive health information of the pregnant women in the gestational period according to a preset period; the comprehensive health information is input into a gestational diabetes health status assessment model, and the comprehensive health status assessment result of the pregnant woman gestational diabetes is predicted, and the comprehensive health status assessment result comprises the risk probability of hyperglycemia, hypoglycemia and gestation complications; according to the gestational diabetes mellitus medical knowledge base and the comprehensive health state evaluation result, a pregnant woman personalized intervention scheme is generated and uploaded to a medical platform for an attending physician to check and confirm, and the pregnant woman personalized intervention scheme comprises diet suggestions, exercise suggestions and medicine adjustment suggestions. The risk probability of the pregnant woman suffering from hyperglycemia, hypoglycemia and pregnancy complications is predicted through the gestational diabetes health status assessment model, personalized risk assessment is realized, and the risk of complications is reduced through a personalized intervention scheme.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH

Liquid formulations of glucagon analogs

The present invention relates to formulations of glucagon analogues or pharmaceutically acceptable salts and / or derivatives thereof; and their medical use, e.g. in the treatment of hypoglycemia. In particular, the present invention relates to stable aqueous liquid formulations of glucagon analogues comprising a combination of excipients that make them suitable for long-term storage as liquids and capable of being used in single dose (SD) or multiple dose (MD) formulations.
Owner:ZEALAND PHARMA AS

Particle structure of peptides extracted from Murray cod

The particle structure of Murray cod extract peptides is provided. [Solution] The particle structure 1 of the Murray cod extract peptide is mainly a spherical structure, and the inside of the spherical structure contains a Murray cod extract peptide layer 10, and the carrier 20 is located on the outer layer of the Murray cod extract peptide layer and covers the Murray cod extract peptide layer. It can be taken orally or wiped externally, and can prevent kidney stones, help glucose metabolism, relieve hypoglycemia, and improve body energy. Murray cod extract peptide is one of the energy sources for muscle tissue and the brain central nervous system, and can help the production of antibodies and aid the metabolism of carbohydrates and organic acids.
Owner:TAIWAN GOODWILL MURRAY PEPTIDE TECHNOLOGIES LNC

Prodrug peptides with improved pharmacological properties

The present disclosure relates to a prodrug peptide, or a salt thereof, having an improvement in at least one biological property compared to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of: therapeutic index, stability, solubility, toxicity, adsorption and pre-systemic metabolism. The prodrug peptide comprises the following structure: Z-pep, wherein: pep is a parent peptide or peptidomimetic; Z is a sequence of n amino acids, Z is cleaved in vivo to release pep; n≥2 amino acids. The present disclosure also relates to methods for preparing and using the prodrug peptides of the present disclosure. For example, the present disclosure describes a prodrug peptide that can be used to prevent, treat or improve at least one symptom of hypoglycemia or a hypoglycemia-related disease or condition.
Owner:IMMUPHARMA (FRANCE) SA

Glucose Responsive Color Changing Tattoo Ink

The present invention relates to a biocompatible tattoo ink that changes color in response to varying glucose levels in the bloodstream, providing a continuous monitoring method for individuals with diabetes. The ink contains glucose-sensitive agents that cause the tattoo to change from green (normal glucose levels) to red (high glucose levels) or blue (low glucose levels). Additionally, the ink shifts back to green when blood glucose returns to normal from either hyperglycemia or hypoglycemia. This provides a real-time visual indicator of glucose levels and enables users to monitor their health without additional equipment.
Owner:AMC TATTOOS LLC

Insulin receptor modulation for tumor associated hyperinsulinism

PCT designated stageWO2025171378A1Metabolism disorderAntibody ingredientsAnti-insulin receptor antibodyAntiendomysial antibodies
The present disclosure describes the use of an anti-insulin receptor antibody to treat neoplasms and / or tumor-associated hyperinsulinism and resulting hypoglycemia caused by benign or malignant neoplastic production of insulin and / or other effector substances (e.g., IGF-2 or its variants) that interact with the INSR and thus result in insulin-like action.
Owner:REZOLUTE INC

Prediction of physiological parameter

Disclosed herein are techniques related to predicting a physiological condition of a user. In some embodiments, the techniques may involve obtaining one or more glucose concentration values measured from a user; applying, to the one or more glucose concentration values measured from the user, a first glucose prediction model for a first prediction horizon; obtaining, based on applying the first glucose prediction model, a first predicted glucose value of the user; and predicting a second predicted glucose value of the user for a second prediction horizon that is less than the first prediction horizon, based on the first predicted glucose value and at least one glucose concentration value of the one or more glucose concentration values. In some scenarios, the physiological condition may include, for example, hypoglycemia or hyperglycemia.
Owner:MEDTRONIC MINIMED INC

Liquid formulations of glucagon analogues

The present invention relates to formulations of glucagon analogues, or a pharmaceutically acceptable salt thereof and / or a derivative thereof; and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable aqueous liquid formulations of glucagon analogues comprising combinations of excipients that make them suitable for long term storage as liquids, and are capable of use in single-dose (SD) or multi-dose (MD) formulations.
Owner:ZEALAND PHARMA AS

Phenylboronic-acid-based insulin derivative, and preparation method therefor and use thereof

The present invention belongs to the technical field of insulin derivatives. Disclosed are a phenylboronic-acid-based insulin derivative, and a preparation method therefor and the use thereof. The provided phenylboronic-acid-based insulin derivative has a good glucose-responsive release function, wherein the phenylboronic acid group binds to a glycosyl protein to generate a phenylboronic acid ester bond, thereby generating an insulin and glycosyl protein complex in situ in blood. When the concentration of glucose in the blood is high, the glucose specifically cleaves the phenylboronic acid ester bond, thereby releasing the insulin. The provided phenylboronic-acid-based insulin derivative achieves stable and rapid glucose-responsive insulin release, which can steadily and persistently maintain the blood glucose of a diabetic subject within the normal range with almost no occurrence of hypoglycemia.
Owner:ZHEJIANG UNIV

Sugar-responsive molecular connector as well as preparation method and application thereof

According to the sugar-responsive molecular connector and the preparation method and application thereof provided by the invention, a brand new sugar-responsive molecular connector compound is formed by esterification and combination of a phenylboronic acid analogue and a 1, 3-diol structure, and the compound can be directly biologically linked with insulin through amidation and has a very good glucose-responsive function; high-concentration glucose can be competitively combined with a 1, 3-diol structure and phenylboronic acid, so that the solubility of insulin is increased, and the release of insulin is promoted; when the concentration is low, only a small part of insulin is in a free state, so that the occurrence of hypoglycemia is reduced. The compound utilizes a brand new mechanism to realize sugar response of insulin, so that the sugar response effect is more sensitive, and the compound is simple in structure, easy to prepare, low in cost and extremely high in clinical application value.
Owner:ZHEJIANG UNIV

Corn silk glucomannan, preparation method and application thereof

The application discloses corn silk glucan, a structure formula of which is [→4)-β-D-Glcp-(1→]n, wherein n is 6-60, and a molecular weight range is 1-9.8 kDa. By extracting effective components in corn silk, an extract is obtained, the extract is precipitated by 30-90% ethanol, corn silk crude polysaccharide is obtained, and after the corn silk crude polysaccharide is dissolved, the corn silk crude polysaccharide is sequentially subjected to biological membrane dialysis, ion exchange resin column and HPLC-ELSD separation and purification, and corn silk glucan is obtained. The corn silk glucan and zeaxanthin are compounded to form a glucan compound, the glucan compound can stabilize insulin and improve the activity of the insulin in mouse islet cells, and the glucan compound has 2-5 times stronger hypoglycemic activity than that of zeaxanthin alone, and therefore, the glucan compound has important significance for researching new hypoglycemic drugs or health-care food for assisting hypoglycemia.
Owner:MACAU UNIV OF SCI & TECH

Noninvasive system and method for measuring hypoglycemia and hyperglycemia

A wearable unit is provided including a plurality of sensors including a temperature sensor configured to sense a temperature of a patient, a pulse oximeter configured to sense an oxygen saturation of the patient, an accelerometer configured to sense a breathing pattern of the patient, a skin conductance sensor configured to sense a skin conductance of the patient, and an electrocardiogram (ECG) monitor configured to sense an ECG pattern of the patient. The wearable unit may be configured to be worn on the patient's wrist or may be configured to be worn in the patient's ear. Information output by the sensors may be used to determine whether the patient is hyperglycemic or hypoglycemic and to provide an alert the patient or patient's caregiver. Information from the wearable unit may be wirelessly transmitted to an external device.
Owner:BECTON DICKINSON & CO

Adjustment of medicament delivery by a medicament delivery device based on menstrual cycle phase

PendingUS20260083912A1ElectrocardiographyDrug and medicationsMenstrual cycle phaseControl system
Exemplary embodiments account for differing needs of a user over the menstrual cycle of the user to better control the blood glucose concentration of the user. The exemplary embodiments may be realized in control systems for medicament delivery devices that deliver medicaments, such as medicaments that regulate blood glucose concentration levels. Examples of such medicaments that regulate blood glucose concentration levels include insulin, glucagon, and glucagon peptide-1 (GLP-1) agonists. The exemplary embodiments are able to better tailor the dosages of the medicament delivered to the user with the medicament delivery device to reduce the risk of hyperglycemia and hypoglycemia and help reduce blood glucose concentration excursions.
Owner:INSULET CORP

Glucose monitoring method and system

This invention provides a system and method to protect an artificial pancreas' sensor, infusion system, and alert systems from EMI / wireless attacks using a medical software or application, close the gap between sensor glucose and blood glucose, and build a non-invasive hypoglycemia and hyperglycemia false alarm detection scheme with the help of a wristband. This inventive method and system provides a more accurate blood glucose prediction. It comprises preprocessing the CGM readings with Kalman smoothing for sensor error correction improves the robustness of the BG prediction. In one or more embodiments, the inventive system and method uses one or more physiological information such as meal, insulin, aggregations of step count, and preprocessed CGM data. The invention provides a novel approach for leveraging the stacked LSTM based deep RNN model to improve the BG prediction accuracy. The invention provides a special circuits-Transduction Shield-to detect and correct the sensor errors caused by EMI attacks.
Owner:UNIVERSITY OF LOUISIANA AT LAFAYETTE